New Healthcare research report from Business Monitor International is now available

July 11, 2010 - PRLog -- BMI's Business Environment Ratings for the Middle East and Africa (MEA) pharmaceutical market underlines some of our key views for how the sector is performing in emerging markets. In particular we highlight Saudi Arabia, Egypt and Ghana as the most positive and promising, while the UAE and South Africa will continue as the main investment focus.

In BMI Business Environment Rating matrix for Q310, Oman fell to tenth, out of the 19 regional markets surveyed in the Middle East and Africa (MEA) region. Although Oman's strict price controls and small population continue to keep the overall pharmaceutical values at levels virtually negligible in global terms, the country does offer some draws, including its preference for branded products, a low-cost manufacturing base and an improved IP environment. In addition, the country's healthcare system is advanced and is highly regarded around the world.

In 2009, Oman's pharmaceutical market was valued at OMR48mn (US$124mn). Prescription medicines accounted for 88% of total drug expenditure in 2009, with the over-the-counter products (OTC) segment at only 10.8%. Patented medicines accounted for 83% of the total market while generic drugs lagged behind at only 6%. Overall, by 2014, the drug market value is forecast to reach OMR66mn (US$170mn), equating to a compound annual growth rate (CAGR) of 5.12% in local currency terms and 6.58% in US dollar terms, with generic medicines and OTCs gaining limited market shares at the expense of patented drugs. Over the extended 2009-2019 forecast period we calculate that Oman's pharmaceutical spending will reach a value of OMR79mn (US$202mn). The pharmaceutical market will remain highly reliant on imports.

In what we view as positive news for Oman's local pharmaceutical industry, in May 2010, Oman Pharmaceutical Products (OPP) announced the US FDA approval for one of its antibiotic products which will result in the drug's export to the US. The Oman-based generic drugmaker will be able to boost its sales through the lucrative US healthcare market and, more significantly, will be exporting an essential medicine which is sure to experience a rapid rise in demand after the healthcare reform and later, the patent cliff, in the US. By approving the product, the FDA joins a list of other regulatory bodies, including those in Australia, Germany and the UK, a scenario which points to OPP's long-term strategic plan to expand into developed markets. Furthermore, for domestic firms, diversifying the economy through long-term manufacturing plants and ensuring that output can be exported will maintain revenues and should also supply local demand. OPP's first US FDA approval also underlines the potential for drugmakers to also attain Good Manufacturing Practice (GMP) accreditation in order to export to the US.

For more information or to purchase this report, go to:
-  http://www.fastmr.com/prod/71690_oman_pharmaceuticals_hea...

Partial Table of Contents:

Executive Summary
SWOT Analysis
- Oman Pharmaceuticals And Healthcare Industry SWOT
- Oman Political SWOT
- Oman Economic SWOT
- Oman Business Environment SWOT
Pharmaceutical Business Environment Ratings
- Table: Middle East And Africa (MEA) - Regional Pharmaceutical Business Environment Ratings, Q310
- Limits Of Potential Returns
- Risks To Realisation Of Returns
Oman - Market Summary
Regulatory Regime
- Recent Regulatory Developments
- Intellectual Property Regime
- Table: Current IP Laws In Oman
- Pricing And Reimbursement
- Regional Price Harmonisation
- Pharmaceutical Industry Developments
- Free Trade Agreements
Industry Developments
- Epidemiology
- Table: Oman Mortality Indicators, 2006
- Healthcare Sector
- Table: Number Of Health Centres In Oman, By Region
- Table: Number And Type Of Health Institutions In Oman
- Private Healthcare Sector
- Healthcare Funding
- Healthcare Reforms
- Table: Healthcare Reform Targets
- Medical Tourism
- International Healthcare Collaboration
- International Pharmaceutical Collaboration
- Research And Biotechnology
- Medical Devices
Industry Forecast Scenario
- Overall Market Forecasts
- Key Growth Factors - Industry
- Key Growth Factors - Macroeconomic
- Table: Oman - Economic Activity
- Prescription Drug Market Forecast
- Patented Drug Market Forecast
- Generic Drug Market Forecast
- OTC Drug Market Forecast
- Pharmaceutical Trade Forecast
- Other Healthcare Data Forecasts
- Key Risk To BMI's Forecasts
Competitive Landscape
- Pharmaceutical Sector
- Table: Registered Pharmaceutical Companies And Products
- Domestic Industry
- Foreign Industry
- Recent Industry Developments
Company Monitor
- Indigenous Manufacturers
- Zynova/Oman Pharmaceutical Products (OPP)
- National Pharmaceutical Industries (NPI)
- Multinationals
- Novartis
- Johnson & Johnson
Country Snapshot: Oman Demographic Data
- Section 1: Population
- Table: Demographic Indicators, 2005-2030
- Table: Rural/Urban Breakdown, 2005-2030
- Section 2: Education And Healthcare
-

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=7169...

About Business Monitor International

Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets.  BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports.  Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports.  View more research from Business Monitor International at http://www.fastmr.com/catalog/publishers.aspx?pubid=1010

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.